Hematology
Prescribing 20 mg of Mozart for Chemotherapy-Induced Nausea
June 20, 2022
Article
A Michigan State University investigator is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.
DRd Outperforms Rd in Newly Diagnosed Multiple Myeloma
June 19, 2022
Article
Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.
The Future of CAR T-Cell Therapy: Will Off-the-Shelf Options Soon Enter the Playing Field?
June 15, 2022
Article
Approval of off-the-shelf CAR T-Cell therapy options would provide greater accessibility and benefit to patients, say experts.
Ilene Galinsky Highlights Optimal Venetoclax Dosing Strategies in AML
June 14, 2022
Video
Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner at Dana-Farber Cancer Institute, underscores key prescribing considerations with venetoclax.
RVd Plus ACST and Lenalidomide Maintenance Promote Efficacy in Newly Diagnosed Multiple Myeloma
June 08, 2022
Article
Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.
The Basics of Biosimilars for Oncology Nurses
June 03, 2022
Article
Kellie Zeichner, RN, BSN, OCN, discusses the production of biosimilars, their approval and naming processes, and why immunogenicity is important when discussing these agents.
Addition of Sorafenib to Chemotherapy Found to be Safe, Effective in Pediatric FLT3-ITD+ AML
June 01, 2022
Article
Standard chemotherapy plus sorafenib achieved clinical benefit in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.
Edema and Effusion With Loncastuximab Tesirine Is Manageable in Patients With Relapsed/Refractory DLBCL
May 29, 2022
Article
Nurse investigators characterized the onset and management of edema and effusion with loncastuximab tesirine in the pivotal LOTIS-2 trial.
Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma
May 28, 2022
Article
Tisagenlecleucel received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations
May 25, 2022
Article
Ivosidenib plus azacitidine received FDA approval for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) harboring IDH1 mutations.